Connect Biopharma Holdings Limited (CNTB) News
Filter CNTB News Items
CNTB News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
CNTB News Highlights
- CNTB's 30 day story count now stands at 3.
- Over the past 7 days, the trend for CNTB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CNTB are LUNG, BHC and DEC.
Latest CNTB News From Around the Web
Below are the latest news stories about CONNECT BIOPHARMA HOLDINGS LTD that investors may wish to consider to help them evaluate CNTB as an investment opportunity.
Are Medical Stocks Lagging Bausch Health (BHC) This Year?Here is how Bausch Health (BHC) and Connect Biopharma Holdings Limited Sponsored ADR (CNTB) have performed compared to their sector so far this year. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayChecking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading! |
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent AsthmaThe global trial met its primary endpoint showing both doses of rademikibart treatment significantly improved lung function at Week 12The significant improvement in lung function was observed as early as Week 1 and was sustained through Week 24 with both doses of rademikibartSignificant improvement in asthma control occurred early and was sustained through Week 24 for both doses of rademikibartSafety results suggest rademikibart was generally well toleratedA conference call and webcast presentat |
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patient |
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus ManagementDallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact on patients, particularly those suffering from Primary Biliary Cholangitis (PBC), an autoimmune liver disease. ... |
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and DexCom (DXCM) have performed compared to their sector so far this year. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday as we check out all of the biggest movements happening this morning! |
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater ChinaSimcere has been granted an exclusive right to develop, manufacture, and commercialize rademikibart for all indications in Greater ChinaConnect Biopharma retains rights to develop and commercialize rademikibart in all other markets and completed the pivotal atopic dermatitis (AD) trial in ChinaRademikibart is a human monoclonal antibody against IL-4Rα, a common subunit for IL-4R and IL-13 receptors being developed for the treatment of Th2 driven inflammatory diseases SAN DIEGO, CA and TAICANG, C |
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic DermatitisClinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and every four weeks (Q4W) dosing regimens Approximately 90% of patients on Q4W dose maintained both IGA 0/1 and EASI-75 through Week 52 Over 36 weeks of treatment in Stage 2 of the study, the percentage of patients achieving IGA 0/1 and EASI-75 continued to increaseRademikibart continued to be well tolerated over 52 weeks of treatmentA conference |
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will announce topline results from the Stage 2 (maintenance period) of its China pivotal trial evaluating rademiki |